March 21, 2005 Biotech traded higher all day on Monday, rising on positive clinical news. The Centient Biotech 200 was up 20.65 points at 3207.88, a rise of .65%. Other indexes didn’t fare as well, with the NYSE Composite taking the worst hit. It sank .65%, while Nasdaq was virtually flat, dropping just .01%. Onyx and Bayer said Bay 43-9006 delayed time-to-progression in kidney cancer, while Novartis and Schering said their colon cancer drug did not perform well, something that helped the stock prices of rivals. Medicis bought Inamed, which makes breast implants and facial wrinkle products, Ista will conduct a Phase IIb trial of its dry eye medication, and Bioenvision said Clofarabine was effective against Acute Myeloid Leukemia. More details...
